Nabota records KRW 92B in North American sales in Q2

K-Botulinum toxin posts record sales in Q2 this year

Nabota-approved countries increase…green light lit to achieving this year's performance target

Sales in the first half of the year recorded KRW 170 billion... signals the achievement of this year's performance target

Evolus has posted record quarterly sales thanks to a surge in sales of its botulinum toxin Nabota.

 

The company generated USD 126 million in sales in the first half of the year, lighting a green light to achieving its performance target for the year.

 

Evolus plans to continue to grow sales by expanding Nabota's international approvals and launching new filler products to market.

 

According to industry sources on the 2nd, Evolus' revenue in Q2 this year was USD 66.9 million (KRW 92 billion), up 35.6% from the USD 49.35 million it had made in the same period a year ago.

 

Evolus

Most of Evolus' revenue came from sales of Nabota (U.S.

 

brand name: Jeuveau).

 

Daewoong Pharmaceutical signed a supply agreement with Evolus in 2013 worth USD 296.8 million (approximately KRW 375 billion).

 

Evolus then introduced Nabota to the North American market in 2020.

 

Nabota was first approved in the North American market.

 

Nabota was initially approved in Canada in 2018, then in the U.S.

 

in February 2019.

 

Since then, Nabota has been further approved in Europe, Australia, Russia, South Africa, and Japan.

 

Evolus' revenue has been increasing steadily since Nabota’s launch in North America in 2020.

 

In Q1 2021, when Nabota was launched, Evolus posted revenue of USD 13.5 million, but the amount increased 151.9% to KRW 34 million in Q1 2022.

 

Evolus surpassed USD 50 million in quarterly revenue for the first time in Q3 last year.

 

Evolus' revenue continued to grow this year as well.

 

In Q1 of this year, the company generated USD59.3 million in revenue, and Q2 revenue was KRW 66.9 million, breaking its record every quarter.

 

Evolus is also looking to expand into the European market upon the official launch of Nabota in Spain in June.

 

In Europe, Nabota is currently available under the brand name Nuceiva in Spain, the United Kingdom, Germany, Austria, and Italy.

 

Botulinum toxin Nabota(U.S.

 

brand name:Jeuveau)

Evolus added 770 new Nabota accounts in Q2.

 

The company has increased the number of customers who have purchased Nabota since its launch to 14,000.

 

The reorder rate of Nabota users is 70%.

 

The growth of Nabota puts Evolus on track to meet the revenue goals it set last year.

 

Evolus had set a revenue target of USD 265 million (KRW 350 billion) this year.

 

In the first half of the year alone, the company achieved about half of its annual target, generating USD 126 million.

 

In addition to Nabota, Evolus is looking to expand sales through new filler products.

 

In May last year, the company secured exclusive U.S.

 

sales and distribution rights to a filler developed by France's Symatese.

 

Evolus recently submitted a premarket approval application (PMA) to the U.S.

 

Food and Drug Administration (FDA) for 2 filler products, Evolysse and Evolysse Lift.

 

The company expects the two to be approved in Q2 next year